Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology
®
Neoadjuvant HER2+
Bone Metastases
Brain Cancer
Business Management
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Genitourinary Cancers
Head & Neck Cancers
Hematologic Oncology
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Non-Hodgkin Lymphoma
Oncology Nursing News
Patient Resources
Sarcomas/TGCT
Special Reports in Personalized Cancer Care
Supportive Care
Online CME
Interactive Publications
SELECT A TOPIC
CURRENT VIEW
All Specialties
▲
Education ▲
Education ▼
Register
|
Login
Conference Coverage
Videos
NewsNetwork
OncLive
®
TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology
®
Neoadjuvant HER2+
More >>
OncLive TV: Joshua Sabari, MD
<< Back to Our Featured Experts
Dr. Sabari on Future of Immunotherapy in SCLC
Dr. Sabari on Immunotherapy Updates in Small Cell Lung Cancer
Oncology Specialists
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Gregory E. Idos, MD
James K. McCloskey II, MD
Charles A. (Trey) Leath III, MD
Charles A. Leath III, MD
David H. Ilson, MD, PhD
Raghava R. Induru, MD
Jeffrey R. Infante, MD
Brant Inman, MD
George N. Ioannou, MD
Syma Iqbal, MD
Luisa Iruela-Arispe, PhD
Melinda L. Irwin, PhD
Claudine Isaacs, MD
Tim Iveson, MD, FACP
Toshiaki Iwase, MD
Hiroji Iwata, MD, PhD
Puneeth Iyengar, MD
Gopa Iyer, MD
Renuka Iyer, MD
OncLive News Network On Location: ASH 2019 Day 3
Trending Now
Chemoimmunotherapy Role in CLL Shifting With Rise of Novel Agents
Adjuvant Pertuzumab Regimen Shows Modest OS Benefit in HER2+ Early Breast Cancer
Tucatinib Boosts Survival in HER2+ Breast Cancer, FDA Submission Imminent
OncLive News Network On Location: ASH 2019 Day 2
Publications
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
x
Subscribe